Peter Heerma Sells 7,215 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Peter Heerma sold 7,215 shares of the stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $41.93, for a total value of $302,524.95. Following the sale, the insider owned 138,608 shares in the company, valued at approximately $5,811,833.44. This represents a 4.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Peter Heerma also recently made the following trade(s):

• On Tuesday, February 3rd, Peter Heerma sold 7,310 shares of Travere Therapeutics stock. The stock was sold at an average price of $32.12, for a total value of $234,797.20.

Travere Therapeutics Price Performance

Shares of NASDAQ TVTX opened at $40.95 on Thursday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 2.70 and a current ratio of 2.74. Travere Therapeutics, Inc. has a fifty-two week low of $13.88 and a fifty-two week high of $43.31. The stock has a market cap of $3.78 billion, a PE ratio of -136.50 and a beta of 0.86. The stock has a fifty day moving average of $29.57 and a 200-day moving average of $31.37.

Key Stories Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: FDA grants full approval for Filspari in FSGS, expanding Travere’s U.S. addressable market by ~30,000 patients and improving the drug’s commercial upside—primary driver of the recent re?rating. Filspari Wins Full Approval — Seeking Alpha
• Positive Sentiment: Market reacted sharply: shares jumped ~37% on the approval as investors priced in first?mover status, premium pricing potential and multi?year revenue upside for Filspari. TVTX Stock Soars on FDA Nod — Zacks
• Positive Sentiment: Multiple brokerages raised ratings/targets (examples: Canaccord to $56, Guggenheim to $54, Piper Sandler to $49, Wedbush higher), signaling stronger analyst conviction for revenue/earnings upside post?approval. Brokerage Upgrades — Benzinga
• Neutral Sentiment: Unusually high options activity and elevated trading volume around the approval indicate heightened short?term speculation and potential for amplified intra?day volatility. Unusually High Options Trading — American Banking News
• Neutral Sentiment: Institutional notes (e.g., Guggenheim forecast lift) and company transcripts/coverage are supplying more detail for modeling uptake, but concrete commercial metrics (pricing, early uptake) are not yet available. Guggenheim Forecast — American Banking News
• Negative Sentiment: Large insider share sales were reported this week (CEO sold 64k shares; multiple officers/directors sold portions). Most trades were executed under pre?arranged Rule 10b5?1 plans and for tax withholding on vesting awards, which reduces the likelihood of negative insider?confidence interpretation but still adds supply and headline risk. Insider Filings (CEO sale) — SEC
• Negative Sentiment: Some analysts warn that recent earnings?estimate revision trends and elevated expectations could limit near?term upside and raise pullback risk after the big move. Near?term Upside Caution — Zacks

Institutional Trading of Travere Therapeutics

A number of large investors have recently modified their holdings of the business. Arizona State Retirement System increased its holdings in Travere Therapeutics by 1.5% during the 3rd quarter. Arizona State Retirement System now owns 24,964 shares of the company’s stock valued at $597,000 after purchasing an additional 375 shares during the period. Smartleaf Asset Management LLC lifted its holdings in Travere Therapeutics by 69.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,193 shares of the company’s stock worth $45,000 after buying an additional 487 shares during the period. Comerica Bank lifted its holdings in Travere Therapeutics by 77.5% in the 4th quarter. Comerica Bank now owns 1,127 shares of the company’s stock worth $43,000 after buying an additional 492 shares during the period. ProShare Advisors LLC grew its position in shares of Travere Therapeutics by 4.1% in the 4th quarter. ProShare Advisors LLC now owns 19,007 shares of the company’s stock worth $726,000 after buying an additional 756 shares during the last quarter. Finally, Diversified Trust Co grew its position in shares of Travere Therapeutics by 3.5% in the 3rd quarter. Diversified Trust Co now owns 23,695 shares of the company’s stock worth $566,000 after buying an additional 796 shares during the last quarter.

Analyst Upgrades and Downgrades

TVTX has been the topic of several analyst reports. JPMorgan Chase & Co. decreased their price target on Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 25th. Citigroup raised their price objective on shares of Travere Therapeutics from $48.00 to $53.00 and gave the company a “buy” rating in a research report on Tuesday. Guggenheim boosted their price objective on shares of Travere Therapeutics from $49.00 to $54.00 and gave the company a “buy” rating in a research note on Tuesday. Piper Sandler raised shares of Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 target price on the stock in a report on Tuesday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, January 21st. Eleven analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Travere Therapeutics has an average rating of “Moderate Buy” and an average target price of $42.50.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.